Drug Class Detail

Drug Class CRAF Inhibitor


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
RAF265 BRAF Inhibitor 18 CRAF Inhibitor 10 VEGFR2 Inhibitor 34 RAF265 inhibits the activities of several intracellular kinases, including BRAF(V600E), BRAF(wild type), c-RAF (RAF1), VEGF receptor 2 (VEGFR2/KDR), platelet-derived growth factor receptor (PDGFR), colony-stimulating factor (CSF)1R, RET and c-KIT, SRC, STE20, which may result in a reduction of tumor cell growth and proliferation, and tumor cell death (PMID: 22351689; NCI Drug Dictionary).
GW5074 CRAF Inhibitor 10 GW5074 inhibits C-Raf resulting in decreased downstream signaling, and potentially leading to reduced tumor cell growth (PMID: 16546979, PMID: 19737955).
PLX8394 BRAF Inhibitor 18 CRAF Inhibitor 10 PLX8394 is a RAF inhibitor that inhibits wild-type and mutant BRAF, as well as CRAF, and does not paradoxically activate MAPK signaling, potentially resulting in decreased proliferation of BRAF-mutant tumor cells (PMID: 26466569, PMID: 24283590).
SKLB646 BRAF Inhibitor 18 CRAF Inhibitor 10 SRC Inhibitor 26 VEGFR2 Inhibitor 34 SKLB646 is a multi-kinase inhibitor with activity against Src, Kdr (Vegfr2), Braf and Craf, resulting in decreased downstream signaling and potentially leading to reduced tumor growth (PMID: 26721945).
RAF709 BRAF Inhibitor 18 CRAF Inhibitor 10 RAF709 is an ATP-competitive inhibitor that inhibits both BRAF monomers and RAF dimers, resulting in growth inhibition in tumor cells (PMID: 29343524).
RXDX-105 AC013773|CEP-32496 ABL Inhibitor (pan) 8 ABL1 Inhibitor 4 BCR-ABL Inhibitor 23 BRAF Inhibitor 18 CRAF Inhibitor 10 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 RET Inhibitor 36 VEGFR2 Inhibitor 34 RXDX-105 (CEP-32496) inhibits wild-type BRAF, BRAF V600E, c-RAF, ABL1 (and BCR-ABL), c-KIT, RET, PDGFR beta, and VEGFR2, potentially resulting in decreased tumor growth (PMID: 22319199).
HM95573 BRAF Inhibitor 18 CRAF Inhibitor 10 HM95573 selectively inhibits BRAF and CRAF, resulting in growth inhibition in tumor cells (Cancer Res 2015;75(15 Suppl):Abstract nr 2607).
Regorafenib Stivarga BAY 73-4506 BRAF Inhibitor 18 CRAF Inhibitor 10 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 RET Inhibitor 36 VEGFR Inhibitor (Pan) 29 VEGFR2 Inhibitor 34 Stivarga (regorafenib) is an inhibitor of several kinases including VEGFR, RET, KIT, PDGFR and RAF, thereby inhibiting tumor angiogenesis and tumor cell proliferation (PMID: 24756792). Stivarga (regorafenib) is FDA approved for colorectal cancer, hepatocellular carcinoma, and GIST (FDA.gov).
ZM336372 CRAF Inhibitor 10 ZM336372 is a small molecule RAF1 inhibitor that paradoxically causes RAF1 activation through a putative feedback mechanism, resulting in decreased proliferation and cell cycle inhibition in carcinoid tumor cells (PMID: 15956248).
GDC0879 GDC-0879 BRAF Inhibitor 18 CRAF Inhibitor 10 GDC0879 is a selective small molecular inhibitor of BRAF and CRAF (RAF1), which inhibits survival of tumor cells (PMID: 19276360).
Molecular Profile Protein Effect Treatment Approaches